David G T Whitehurst1, Stirling Bryan, Martyn Lewis, Elaine M Hay, Ricky Mullis, Nadine E Foster. 1. *Faculty of Health Sciences, Blusson Hall, Simon Fraser University, Burnaby, British Columbia, Canada †Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada ‡School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada §Arthritis Research UK Primary Care Centre, Institute for Primary Care and Health Sciences, Keele University, Staffordshire, United Kingdom; and ¶Department of Public Health & Primary Care, Primary Care Unit, University of Cambridge, United Kingdom.
Abstract
STUDY DESIGN: Within-study cost-utility analysis. OBJECTIVE: To explore the cost-utility of implementing stratified care for low back pain (LBP) in general practice, compared with usual care, within risk-defined patient subgroups (that is, patients at low, medium, and high risk of persistent disabling pain). SUMMARY OF BACKGROUND DATA: Individual-level data collected alongside a prospective, sequential comparison of separate patient cohorts with 6-month follow-up. METHODS: Adopting a cost-utility framework, the base case analysis estimated the incremental LBP-related health care cost per additional quality-adjusted life year (QALY) by risk subgroup. QALYs were constructed from responses to the 3-level EQ-5D, a preference-based health-related quality of life instrument. Uncertainty was explored with cost-utility planes and acceptability curves. Sensitivity analyses examined alternative methodological approaches, including a complete case analysis, the incorporation of non-back pain-related health care use and estimation of societal costs relating to work absence. RESULTS: Stratified care was a dominant treatment strategy compared with usual care for patients at high risk, with mean health care cost savings of £124 and an incremental QALY estimate of 0.023. The likelihood that stratified care provides a cost-effective use of resources for patients at low and medium risk is no greater than 60% irrespective of a decision makers' willingness-to-pay for additional QALYs. Patients at medium and high risk of persistent disability in paid employment at 6-month follow-up reported, on average, 6 fewer days of LBP-related work absence in the stratified care cohort compared with usual care (associated societal cost savings per employed patient of £736 and £652, respectively). CONCLUSION: At the observed level of adherence to screening tool recommendations for matched treatments, stratified care for LBP is cost-effective for patients at high risk of persistent disabling LBP only. LEVEL OF EVIDENCE: 2.
STUDY DESIGN: Within-study cost-utility analysis. OBJECTIVE: To explore the cost-utility of implementing stratified care for low back pain (LBP) in general practice, compared with usual care, within risk-defined patient subgroups (that is, patients at low, medium, and high risk of persistent disabling pain). SUMMARY OF BACKGROUND DATA: Individual-level data collected alongside a prospective, sequential comparison of separate patient cohorts with 6-month follow-up. METHODS: Adopting a cost-utility framework, the base case analysis estimated the incremental LBP-related health care cost per additional quality-adjusted life year (QALY) by risk subgroup. QALYs were constructed from responses to the 3-level EQ-5D, a preference-based health-related quality of life instrument. Uncertainty was explored with cost-utility planes and acceptability curves. Sensitivity analyses examined alternative methodological approaches, including a complete case analysis, the incorporation of non-back pain-related health care use and estimation of societal costs relating to work absence. RESULTS: Stratified care was a dominant treatment strategy compared with usual care for patients at high risk, with mean health care cost savings of £124 and an incremental QALY estimate of 0.023. The likelihood that stratified care provides a cost-effective use of resources for patients at low and medium risk is no greater than 60% irrespective of a decision makers' willingness-to-pay for additional QALYs. Patients at medium and high risk of persistent disability in paid employment at 6-month follow-up reported, on average, 6 fewer days of LBP-related work absence in the stratified care cohort compared with usual care (associated societal cost savings per employed patient of £736 and £652, respectively). CONCLUSION: At the observed level of adherence to screening tool recommendations for matched treatments, stratified care for LBP is cost-effective for patients at high risk of persistent disabling LBP only. LEVEL OF EVIDENCE: 2.
Authors: Dan Cherkin; Benjamin Balderson; Rob Wellman; Clarissa Hsu; Karen J Sherman; Sarah C Evers; Rene Hawkes; Andrea Cook; Martin D Levine; Diane Piekara; Pam Rock; Katherine Talbert Estlin; Georgie Brewer; Mark Jensen; Anne-Marie LaPorte; John Yeoman; Gail Sowden; Jonathan C Hill; Nadine E Foster Journal: J Gen Intern Med Date: 2018-05-22 Impact factor: 5.128
Authors: Dan Cherkin; Benjamin Balderson; Georgie Brewer; Andrea Cook; Katherine Talbert Estlin; Sarah C Evers; Nadine E Foster; Jonathan C Hill; Rene Hawkes; Clarissa Hsu; Mark Jensen; Anne-Marie LaPorte; Martin D Levine; Diane Piekara; Pam Rock; Karen Sherman; Gail Sowden; Rob Wellman; John Yeoman Journal: BMC Musculoskelet Disord Date: 2016-08-24 Impact factor: 2.362
Authors: Nadine E Foster; Kika Konstantinou; Martyn Lewis; Reuben Ogollah; Kate M Dunn; Danielle van der Windt; Ruth Beardmore; Majid Artus; Bernadette Bartlam; Jonathan C Hill; Sue Jowett; Jesse Kigozi; Christian Mallen; Benjamin Saunders; Elaine M Hay Journal: BMC Musculoskelet Disord Date: 2017-04-26 Impact factor: 2.362
Authors: Joanne Protheroe; Benjamin Saunders; Bernadette Bartlam; Kate M Dunn; Vince Cooper; Paul Campbell; Jonathan C Hill; Stephanie Tooth; Christian D Mallen; Elaine M Hay; Nadine E Foster Journal: BMC Musculoskelet Disord Date: 2019-06-01 Impact factor: 2.362
Authors: Niladri K Mahato; Stephane Montuelle; John Cotton; Susan Williams; James Thomas; Brian Clark Journal: BMC Med Imaging Date: 2016-05-18 Impact factor: 1.930